Anatara Lifesciences Strengthens IP Portfolio with Australian Patent for GaRP Product

Key Highlights

• Australian patent for GaRP product valid until October 2040.
• GaRP addresses critical gastrointestinal health issues, including IBS.
• Global non-prescription market for IBS estimated at $8B annually in the US.
• Phase II clinical trial results expected in Q1 2025.

Adelaide, 28 January 2025 – Anatara Lifesciences (ASX: ANR) has solidified its position as a leader in gastrointestinal health innovation with the grant of an Australian patent for its GaRP product, a unique gastrointestinal health composition designed to restore gut lining integrity and microbiome balance. The patent, effective until October 2040, marks another major milestone for the company as it gears up for pivotal clinical trial results in March 2025.

A Step Forward in Gut Health Innovation

The GaRP product, part of Anatara Lifesciences (ASX: ANR) Gastrointestinal ReProgramming initiative, uses a proprietary multi-coated, multi-component approach to address debilitating gastrointestinal conditions like irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

Anatara Lifesciences (ASX: ANR) Executive Chair, Dr. David Brookes, highlighted the strategic importance of this milestone, “The Australian patent grant consolidates the uniqueness of GaRP’s formulation and enhances its commercial potential. With upcoming trial results, GaRP could redefine how gastrointestinal health is managed.”

The patent follows the grant of a similar European patent in September 2024, covering the United Kingdom and Hong Kong, with additional jurisdictions under review.

Clinical Progress: GaRP-IBS Trial

Anatara Lifesciences (ASX: ANR) ongoing Phase II GaRP-IBS trial aims to provide a robust clinical validation of the product’s efficacy. Stage 2 of the trial, which involves 71 participants, builds on the promising results of Stage 1, where over 50% of participants reported significant symptom reduction.

The trial is powered to deliver statistically significant results, and its findings are expected to play a critical role in differentiating GaRP in the competitive IBS treatment market.

Market Opportunity

With the global market for non-prescription gastrointestinal health products valued at $8 billion annually in the United States alone, GaRP is poised to capture a significant share of this growing market.

GaRP’s design targets two key unmet needs:

• Restoring the gut lining as a barrier: This protects against harmful substances and inflammation.
• Maintaining microbiome homeostasis: Promoting a healthy gut environment and reducing IBS symptoms.

The lack of effective IBS treatments highlights a clear opportunity for a product like GaRP, which offers a disease-modifying mechanism of action. The Australian patent complements GaRP’s growing international intellectual property footprint. The European grant, announced in September 2024, extends patent protection across key markets, including the United Kingdom and Hong Kong.

Patent applications in other jurisdictions remain under review, underscoring Anatara Lifesciences (ASX: ANR) commitment to securing global exclusivity for its innovative product.

What’s Next for GaRP?

Looking ahead, Anatara Lifesciences (ASX: ANR) plans to:

• Conclude its Phase II GaRP-IBS trial and release results in Q1 2025.
• Accelerate commercialization strategies, leveraging its robust IP portfolio.

Explore broader indications for GaRP beyond IBS, tapping into a diverse range of gastrointestinal health markets. With its newly granted Australian patent, promising clinical trial progress, and a clear path to commercialization, Anatara Lifesciences (ASX: ANR) is well-positioned to transform gastrointestinal health management. As the global demand for effective, non-prescription gut health solutions continues to rise, GaRP’s innovative approach could set a new standard in the field.